AIIMS Director: Vaccine Trial Results will come by September

AIIMS said that the trial of Covaxin, the corona vaccine of Bharat Biotech Company being made for children in the country,
Image Credit: International Disability Alliance
Image Credit: International Disability Alliance

So far only people above 18 years of age are getting the corona vaccine in India. So far no concrete decision has been taken regarding the vaccination of children. However, a piece of big news has come out about vaccinating children. Dr. Randeep Guleria, Director, All India Institute of Medical Sciences (AIIMS) said that the trial of Kovaxin, the corona vaccine of Bharat Biotech Company being made for children in the country, is going on. According to the AIIMS director, the results of the trial of this vaccine being made for children are expected by September.

AIIMS director says on booster dose and immunity

On the subject of a booster dose, Dr. Randeep Guleria said that to fight new forms of the virus, we may need a booster dose as there will be a decline in immunity over time. He made it clear that the booster dose will be the next-generation medicine. These second-generation vaccines will give excellent immunity, which will be effective and effective against new forms of the virus. These booster doses are currently under trial. According to Randeep Guleria, a booster dose may be needed by the end of this year. But this will happen only once the entire population is vaccinated.

Image Credit: The Print
Image Credit: The Print

The infection rate is low

Dr. Guleria on Saturday (July 23) said, "Bharat Biotech's Covaxin trials for children are currently underway and the results are expected to be released by September." Dr. Guleria said that schools can be opened in the areas where the infection rate is low with full monitoring. In this era of an epidemic, many children had to drop out of school due to the lack of availability of computers and mobiles.

Zydus Cadila completes the first phase of testing

According to the information, Zydus Cadila has completed the trial of its vaccine for children aged 12 to 18 years. However, it will take a few more days for the Drug Controller General of India (DCGI) to allow it for emergency use.

Like and Follow us on :

Related Stories

No stories found.
logo
Since independence
www.sinceindependence.com